خانه › سرطان ریه غیرسلول کوچک › کالیفرنیا › Sacramento
آزمایش‌های بالینی سرطان ریه غیرسلول کوچک در Sacramento، CA
29 مطالعه برای سرطان ریه غیرسلول کوچک در مراکز Sacramento (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
در حال جذب شرکت‌کنندهمرحله 3
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- و 1 مورد دیگر
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
در حال جذب شرکت‌کنندهمرحله 3
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
در حال جذب شرکت‌کنندهمرحله 3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 3
- Buhler Specialty Pavilion, Sacramento
- Sutter Medical Center, Sacramento Infusion Center, Sacramento
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 2
- UC Davis Comprehensive Cancer Center, Sacramento
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
در حال جذب شرکت‌کنندهمرحله 3
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- UC Davis Comprehensive Cancer Center, Sacramento
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
در حال جذب شرکت‌کنندهمرحله 2
- UC Davis Cancer Center (Data Collection Only), Sacramento
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 2
- UC Davis Comprehensive Cancer Center, Sacramento
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
در حال جذب شرکت‌کنندهمرحله 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
در حال جذب شرکت‌کنندهمرحله 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 2
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
در حال جذب شرکت‌کنندهمرحله 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of California Davis Comprehensive Cancer Center, Sacramento
- University of California, Davis Medical Center, Sacramento
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
در حال جذب شرکت‌کننده
- University of California, Davis, Sacramento
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
در حال جذب شرکت‌کنندهمرحله 1/2
- UC Davis, Davis Comprehensive Cancer Center, Sacramento
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
در حال جذب شرکت‌کنندهمرحله 3
- Sutter Institute for Medical Research, Sacramento
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
در حال جذب شرکت‌کنندهمرحله 1
- University of California Davis, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2/3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Kaiser Permanente Downtown Commons, Sacramento
- Mercy Cancer Center - Sacramento, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
- و 1 مورد دیگر
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
در حال جذب شرکت‌کنندهمرحله 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 1/2
- VA Northern California Health Care System, Mather, CA, Sacramento
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 1
- University of California-Davis, Sacramento
آزمایش‌های سرطان ریه غیرسلول کوچک در سایر شهرها
- Houston, TX145 مطالعه
- New York City, NY121 مطالعه
- Arlington, VA104 مطالعه
- Nashville, TN97 مطالعه
- Boston, MA90 مطالعه
- Los Angeles, CA87 مطالعه
- St. Louis, MO73 مطالعه
- Chicago, IL61 مطالعه
- Baltimore, MD60 مطالعه
- San Antonio, TX59 مطالعه
- Columbus, OH57 مطالعه
- Washington, DC55 مطالعه
سایر مطالعات در Sacramento
- سرطان ریه22 مطالعه
- سرطان پستان20 مطالعه
- سرطان پروستات19 مطالعه
- سرطان متاستاتیک16 مطالعه
- لوکمیه حاد میلویید12 مطالعه
- نارسایی قلبی12 مطالعه
- سرطان لوزالمعده12 مطالعه
- سرطان (همه انواع)11 مطالعه
- سرطان کولون11 مطالعه
- سرطان مثانه10 مطالعه
- سرطان کولورکتال10 مطالعه
- دیابت نوع ۲9 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 6 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.